These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20675041)

  • 1. Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide.
    Lu S; Tan Z; Wortman M; Lu S; Dong Z
    Cancer Lett; 2010 Dec; 298(2):250-7. PubMed ID: 20675041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
    Lu S; Wang A; Lu S; Dong Z
    Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
    Zhang Y; Kim KH; Zhang W; Guo Y; Kim SH; Lü J
    Int J Cancer; 2012 Jan; 130(1):200-12. PubMed ID: 21328348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
    Cherian MT; Wilson EM; Shapiro DJ
    J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
    Segal CV; Koufaris C; Powell C; Gooderham NJ
    Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
    Desiniotis A; Schäfer G; Klocker H; Eder IE
    Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
    Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
    Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.
    Danquah M; Duke CB; Patil R; Miller DD; Mahato RI
    Pharm Res; 2012 Aug; 29(8):2079-91. PubMed ID: 22451249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines.
    Katayama H; Murashima T; Saeki Y; Nishizawa Y
    Int J Oncol; 2010 Mar; 36(3):553-62. PubMed ID: 20126974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
    Jin F; Fondell JD
    Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
    Liu S; Qi Y; Ge Y; Duplessis T; Rowan BG; Ip C; Cheng H; Rennie PS; Horikawa I; Lustig AJ; Yu Q; Zhang H; Dong Y
    Mol Cancer Ther; 2010 Jul; 9(7):2016-25. PubMed ID: 20571066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth and migration of LNCaP prostate cancer cells are promoted by triclosan and benzophenone-1 via an androgen receptor signaling pathway.
    Kim SH; Hwang KA; Shim SM; Choi KC
    Environ Toxicol Pharmacol; 2015 Mar; 39(2):568-76. PubMed ID: 25682003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.